Loading
A phase 2 trial of VS-7375, Cetuximab, Panitumumab in colorectal cancer, run by Verastem, Inc., now recruiting.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer is a phase 2 interventional study registered as NCT07659795 by Verastem, Inc., with 150 participants planned, started 2026-07-28 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares VS-7375, Verastem Oncology, Cetuximab.
Shares VS-7375, Verastem Oncology, Cetuximab, Colorectal cancer.
Shares VS-7375, Verastem Oncology.
Shares Panitumumab, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares Panitumumab, Cetuximab, Colorectal cancer.
Shares Panitumumab, Cetuximab, Colorectal cancer.
Shares Panitumumab, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.